MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/120/0.2/21.03.25 | Market Closed - Börse Stuttgart 19:24:34 02/07/2024 BST | ||
| 6.01 EUR | -6.24% |
|
| Current month | -2.44% | ||
| 1 month | +26.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 02/07/24 | 6.01 | -6.24% |
| 01/07/24 | 6.41 | +4.06% |
| 28/06/24 | 6.16 | -1.91% |
| 27/06/24 | 6.28 | -0.32% |
| 26/06/24 | 6.3 | -5.83% |
Delayed Quote Börse Stuttgart
Last update July 02, 2024 at 07:24 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MB5KAY |
| ISIN | DE000MB5KAY0 |
| Date issued | 13/04/2023 |
| Strike | 120 $ |
| Maturity | 21/03/2025 (262 Days) |
| Parity | 5 : 1 |
| Emission price | 0.66 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.69 € |
|---|---|
| Lowest since issue | 0.57 € |
| Spread | 0.02 € |
| Spread % | 0.33% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Warrants
- Warrant
